Hizaar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hizaar

Property Description
Active ingredient Losartan Potassium and Hydrochlorothiazide
Form Film-coated tablet (Oral administration)
Pharmacological class Angiotensin II Receptor Antagonist and Diuretic Combination
General purpose Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Hizaar and What is its Purpose?

Hizaar is a prescription-only, fixed-dose combination product designed for the long-term control of high blood pressure, known as hypertension. This medication is administered orally as a film-coated tablet and is classified as an antihypertensive agent. The primary purpose of this combined formulation is to provide a more robust and sustained reduction in elevated blood pressure compared to a single medication, offering a crucial cardiovascular benefit for adults. Research supports the efficacy of this combination for controlling elevated pressure and improving therapeutic adherence.

The drug is a synthetic compound composed of two distinct active ingredients: Losartan Potassium and Hydrochlorothiazide. Hizaar is specifically recognized for combining these two agents to treat patients for whom monotherapy has proven inadequate. Its strategic design allows patients to receive two essential blood pressure treatments in a single preparation, simplifying the therapeutic approach to managing a chronic condition.


Composition and Pharmacological Classification

Hizaar is classified within the pharmacological class of Angiotensin II Receptor Antagonists and Diuretics, often referred to as an ARB/HCTZ Combo. The medication combines Losartan Potassium, a non-peptide synthetic molecule that functions as an Angiotensin II Receptor Blocker (ARB), with Hydrochlorothiazide, a synthetic Thiazide Diuretic. This combination is utilized in essential hypertension, highlighting its role in initiating or stepping up dual-agent treatment.

This dual composition is deliberate, leveraging two different physiological interventions to manage high blood pressure. Losartan addresses the hormonal aspect of blood pressure regulation, while Hydrochlorothiazide addresses the fluid balance component. The combined strategy ensures comprehensive intervention against the key factors contributing to elevated systemic vascular resistance and fluid volume.


The Dual Mechanism Approach to Blood Pressure Control

The core principle behind Hizaar's function is the synergistic action of its two components, designed to control blood pressure through complementary pathways simultaneously. One component works by allowing blood vessels to relax and widen, while the other encourages the removal of excess salt and water through the kidneys, a process called diuresis. By integrating vessel relaxation with fluid volume reduction, the medication effectively reduces the pressure against the artery walls, easing the workload on the heart. This dual mechanism is clinically recognized for providing effective and sustained blood pressure control, directly supporting the goal of long-term cardiovascular maintenance.

What side effects are possible with Hizaar?

Possible side effects and safety information

The safety profile of Hizaar (Losartan Potassium and Hydrochlorothiazide) is characterized by classifying adverse reactions based on their frequency and the body system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

The officially documented side effects are categorized into frequency bands. Common reactions (occurring in 1 to 10 out of 100 people) primarily involve the nervous system and metabolism, including dizziness, headache, fatigue, and changes in blood chemistry like hyperuricemia and specific electrolyte disturbances.

Uncommon reactions (affecting 1 to 10 out of 1,000 people) include vascular effects such as hypotension (low blood pressure), palpitations, gastrointestinal symptoms like diarrhea and nausea, and skin reactions like rash.

Serious Adverse Reactions and Safety Constraints

The medicine's regulatory label identifies rare but serious adverse reactions, which include severe hypersensitivity events like Angioedema (swelling of the face, lips, throat, and/or tongue) and severe effects on the liver or blood, such as Hepatitis or Aplastic Anemia.

Safety constraints and restrictions are placed on its use in specific patient groups. The medication is contraindicated in conditions such as severe renal impairment (anuria), severe hepatic impairment, and during pregnancy, especially in the later stages, due to the risk of fetal toxicity. Additionally, effects like hypotension and electrolyte changes are noted as more common at the start of treatment or during dose adjustments in susceptible individuals.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Hizaar (Losartan/Hydrochlorothiazide) describes specific clinical manifestations and mandated emergency actions in the event of an overdose.


Documented Overdose Presentations

Feature Official Regulatory Statement
Most Likely Signs Hypotension (abnormally low blood pressure) and Tachycardia (rapid heart rate).
Possible Signs Bradycardia (slow heart rate) may occur due to parasympathetic stimulation.
Severe Outcome Potential for profound symptomatic hypotension compounded by marked volume depletion.

Required Emergency Actions

Feature Official Regulatory Statement
When to Seek Help Immediate medical attention is required for any suspected overdose or if symptomatic hypotension occurs.
Management Supportive treatment must be instituted if symptomatic hypotension is observed. Treatment is typically symptomatic and supportive.
Procedural Note Neither Losartan nor its active metabolite can be effectively removed by hemodialysis.

Profile Summary

The regulatory profile defines an overdose state primarily by its cardiovascular effects, with the occurrence of symptomatic hypotension being the critical event that necessitates the immediate institution of supportive treatment under medical supervision. The official information provides the procedural constraint that the active components are not amenable to removal by hemodialysis.

Therapeutic Uses of Hizaar

What Hizaar Treats: Main Uses and Benefits

Hizaar (Losartan/Hydrochlorothiazide) is generally used in the therapeutic domain of Cardiovascular Medicine for the long-term management of essential high blood pressure (hypertension), a condition presenting with symptoms related to systemic imbalance. This combination is relevant in contexts marked by increased discomfort or tension associated with conditions where symptoms may intensify temporarily, such as when monotherapy is insufficient. The medication is applied in addressing symptoms related to systemic imbalance by simultaneously managing the tightness of blood vessels and excess fluid volume and systemic overload. This dual action contributes to easing the overall symptom load by providing a robust and reliable sustained reduction in pressure. The ultimate therapeutic benefit supports long-term cardiovascular maintenance, which contributes to easing the overall symptom load associated with the chronic condition. This treatment may assist with maintaining functional stability and supports general well-being during symptomatic phases related to the chronic condition.


Quick Fact: Relief for Systemic Pressure and Fluid Overload

Regulatory References

  1. DailyMed (NIH) professional labeling

Eligibility and Restrictions for Use

Hizaar (Losartan/Hydrochlorothiazide) is officially authorized for use in adults for managing high blood pressure, particularly when monotherapy is insufficient. Eligibility is strictly governed by regulatory status concerning age, reproductive state, organ function, and allergies.

Contraindications and Restrictions

Classification Population/Condition Regulatory Status
Absolute Contraindication Second and third trimesters of pregnancy Prohibited
Absolute Contraindication Hypersensitivity to Losartan, HCTZ, or sulfonamide-derived drugs Prohibited
Absolute Contraindication Anuria (no urine output) or Severe Hepatic Impairment Prohibited
Absolute Contraindication Patients with Diabetes Mellitus taking Aliskiren Prohibited
Not Recommended Pediatric patients (lt 18 years of age) Safety/efficacy not established
Not Recommended Severe Renal Impairment ( CrCl le 30 mL/min) Restricted use
Not Recommended Lactation (Breastfeeding) Conditional cessation required

Use is also restricted in patients with volume depletion, which must be corrected prior to initiation. Use requires caution in cases of bilateral renal artery stenosis and mild to moderate hepatic impairment, and is generally not recommended in the first trimester of pregnancy. Geriatric patients do not typically require a dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Hizaar (Losartan/Hydrochlorothiazide) is defined by officially documented risks concerning pharmacodynamic reinforcement and altered substance exposure, based on regulatory labeling.

Documented Co-Administration Restrictions

Co-administration is officially contraindicated with Aliskiren in patients diagnosed with Diabetes Mellitus or existing Renal Impairment due to the enhanced risk of hyperkalemia and decreased renal function. Furthermore, Hizaar is contraindicated in specific patient conditions including Anuria (absence of urine production) and Severe Hepatic Impairment.

Pharmacodynamic and Exposure Effects

Co-administration with agents that increase serum potassium, such as potassium-sparing diuretics and potassium supplements, is not recommended due to the additive pharmacodynamic risk of hyperkalemia (elevated serum potassium levels). Lithium clearance is officially reduced when co-administered, leading to increased serum concentrations and potential toxicity, requiring regulatory surveillance. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the combination’s blood pressure-lowering effect and increase the documented risk of worsening renal function. The Hydrochlorothiazide component may officially impair glucose tolerance, necessitating a potential adjustment of antidiabetic drugs (oral agents or insulin). Alcohol (Ethanol) may result in additive blood pressure-lowering effects, officially documented as increasing the risk of dizziness.

Timing Constraints

The absorption of Hydrochlorothiazide is officially reduced by anionic exchange resins such as Cholestyramine and Colestipol. To ensure adequate exposure, regulatory requirements stipulate that Hizaar must be administered 4 hours before or 4 to 6 hours after the administration of the resin.

Mechanism of Action

How Hizaar Works

Hizaar operates via a dual pharmacodynamic mechanism, combining an angiotensin II receptor blocker with a diuretic.

Angiotensin II Receptor Blockade

The active component losartan and its primary metabolite function as selective antagonists of the angiotensin II type 1 (AT1) receptor. They bind to this receptor in vascular smooth muscle and other target tissues, thereby inhibiting the intense vasoconstrictor and aldosterone-releasing effects mediated by angiotensin II. This antagonism modulates key pathways within the Renin-Angiotensin-Aldosterone System, resulting in the adjustment of peripheral vascular resistance.

Renal Electrolyte Transport Inhibition

Hydrochlorothiazide, the diuretic component, engages a distinct mechanistic domain within the renal system. It acts primarily on the distal convoluted tubules, where it modulates the transport of electrolytes. Specifically, it inhibits the reabsorption of sodium and chloride ions. This modification of early molecular steps within the nephron promotes the increased excretion of salt and water, influencing plasma volume and consequently altering cardiovascular fluid dynamics.

Dosage and Administration Information

How to Use Hizaar: Administration Guidelines

Hizaar is an oral, film-coated tablet administered once daily for the long-term management of high blood pressure. The medication is typically used when control has been inadequate with monotherapy (Losartan or Hydrochlorothiazide alone). The tablet may be taken with or without food and should be swallowed whole with water.


Dosing and Scheduling

The standard regimen begins with a starting dose of 50 mg/12.5 mg (Losartan/Hydrochlorothiazide) once per day. The maximum recommended daily intake is 100 mg/25 mg. If the blood pressure remains uncontrolled, the dosage may be increased after a period of approximately three weeks of therapy. If a dose is missed, individuals should skip the forgotten dose and resume the schedule with the next planned dose; a double dose should not be taken.


Population and Procedural Constraints

The fixed-dose combination product is not recommended for individuals with severe renal impairment (creatinine clearance leq 30 mL/min) or hepatic impairment, as the dose ratio is fixed and cannot be adjusted for these conditions. No initial dosage adjustment is typically required for older adults. Use is not recommended for children and adolescents under 18 years of age due to a lack of established data. This framework ensures the standardized use of the medicine across appropriate patient groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hizaar


Evidence for use in High Blood Pressure (Hypertension)

Hizaar was studied in research exploring how it affects high blood pressure (a condition where symptoms may vary in intensity) across a number of research settings. Studies explored how blood pressure readings changed when Hizaar was observed in participants, measurements that are outcomes related to systemic or functional imbalance. Research examined the use of Hizaar, sometimes compared to an inactive substance (placebo), over defined time intervals.

The findings describe patterns observed in the studies where individuals receiving Hizaar data show patterns related to measured changes in blood pressure readings. These changes was observed in some studies to be a certain magnitude, as measured by the research protocols. However, research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. The evidence contributes to understanding symptom patterns related to this common condition.


Evidence for use in Reducing the Risk of Stroke and Heart Attack

Research was observed in studies to explore the long-term patterns related to serious outcomes (outcomes describing episodic or acute changes) in participants taking Hizaar. Studies followed large groups of people, sometimes for many years, to monitor whether the use of Hizaar appears to influence these outcomes in individuals with high blood pressure and an enlarged heart (left ventricular hypertrophy).

Findings indicate that the research data show patterns related to observed differences in the number of serious outcomes (including stroke) between the different groups was observed in some studies that examined these specific populations. However, the certainty remains low outside of the specific patient populations applied in studies examining patient-reported experiences for these critical outcomes.


Long-term Studies and Follow-up

Studies have monitored the use of Hizaar over extended periods to see if the influence on blood pressure remained consistent. The data show patterns related to blood pressure changes remaining consistent was observed in the studies for the follow-up durations that were measured. However, long-term effects are not fully established beyond the periods studied, and follow-up durations were limited in many cases. Therefore, research provides context but not individual predictions about the durability of this response over a lifetime.

Frequently Asked Questions (FAQ)

Common questions about Hizaar (FAQ)

Q: What is the main difference between Hizaar and just taking Losartan?

A: Hizaar is a fixed-dose combination product containing two active ingredients: Losartan and the diuretic Hydrochlorothiazide. It is typically prescribed when blood pressure has not been adequately controlled by Losartan alone. The combination is designed to provide a comprehensive approach to blood pressure management, which clinical practice indicates can be more effective for some patients compared to monotherapy.


Q: How quickly should I expect Hizaar to start lowering my blood pressure?

A: According to clinical studies, the initial blood pressure reduction is usually noticeable within the first week of starting treatment. The medicine’s full blood pressure-lowering effect generally develops and is assessed after approximately three to four weeks of continuous therapy.


Q: What types of food or drinks should be avoided while taking Hizaar?

A: Official information indicates that intake of alcohol should be monitored, as it may result in additive blood pressure-lowering effects, potentially increasing the risk of dizziness. The product label highlights that salt substitutes, which often contain potassium, can lead to increased potassium levels when co-administered with the Losartan component, necessitating caution or monitoring.


Q: Does Hizaar affect kidney function in the long term?

A: Hizaar is not recommended for individuals with severe existing kidney impairment. The medicine can cause changes in kidney function, including acute kidney failure, particularly in susceptible patients. Due to these risks, official guidelines recommend regular monitoring of kidney function and potassium levels for individuals who may be susceptible to changes.


Q: Is Hizaar safe for people who have diabetes?

A: The combination of Hizaar with the medicine Aliskiren is officially contraindicated (prohibited) in patients with diabetes due to enhanced risks. Additionally, the Hydrochlorothiazide component may impair glucose tolerance, meaning a dosage adjustment of antidiabetic drugs may be needed for monitoring.


Q: Will Hizaar affect my ability to drive or operate machinery?

A: Official guidance warns that caution is necessary when driving or operating machinery. The medicine may cause dizziness or fainting, particularly at the start of treatment or when changing dosage. This caution is particularly relevant while the individual is assessing their response to the medication's potential effects on alertness and motor skills.


Q: Are there any known issues with Hizaar and sexual function?

A: Official regulatory documents indicate that erectile dysfunction, also referred to as impotence, has been reported as a potential adverse reaction. This finding comes from clinical trials and postmarketing experience related to the medication.


Q: What should I do if my side effects from Hizaar don't go away after a few weeks?

A: Official safety constraints note that ongoing severe side effects, such as persistent nausea, vomiting, or diarrhea that do not stop, require medical attention. These symptoms can cause significant loss of water and salt from the body, which may lead to dangerously low blood pressure. If side effects persist, it is important to seek medical attention.


Q: How is Hizaar different from other blood pressure medications like ACE inhibitors?

A: Regulatory documents indicate that Hizaar contains Losartan, which is an Angiotensin II Receptor Blocker (ARB). ARBs work differently from Angiotensin Converting Enzyme (ACE) inhibitors because they do not directly inhibit the ACE enzyme. Clinical studies have noted that the incidence of cough associated with Losartan is reported to be similar to that of an inactive substance (placebo).


Q: Does Hizaar have to be taken at a specific time of day?

A: Hizaar is designed to be administered once daily for the long-term management of high blood pressure. While specific instructions on morning or evening use are not typically provided, the diuretic component may cause increased urination. Because of the potential for increased urination, some official information suggests that the timing of the dose may be adjusted to minimize disruption to sleep.


Q: Is Hizaar commonly prescribed for people who also have heart failure?

A: Hizaar is officially used to treat high blood pressure. The Losartan component has been studied in patients with high blood pressure and left ventricular hypertrophy (enlarged heart). Official information indicates that use in patients with severe congestive heart failure is restricted or requires special monitoring, as there is an increased risk of developing acute kidney failure.


Q: What is the expected maximum blood pressure reduction with Hizaar?

A: Clinical studies have measured the typical blood pressure reduction in patient groups compared to an inactive substance (placebo). Findings indicated a mean reduction of approximately 15.5/9.2 mmHg at the lower combination dose, and 19.1/10.9 mmHg at the higher dose. It is important to note that individual responses may be different.


Q: How long does the effect of one dose of Hizaar usually last?

A: Hizaar is prescribed as a once-daily medicine, reflecting its intended duration of action to provide effective blood pressure control over a full 24-hour period. This dosing schedule is supported by the known half-lives of the active components.


Q: Can Hizaar increase sensitivity to the sun?

A: Yes, the Hydrochlorothiazide component of Hizaar may cause a condition called photosensitivity, which is an increased sensitivity to the sun. The risk of photosensitivity means that protecting the skin from sun exposure is generally recommended during treatment. Additionally, regulatory guidance recommends regular skin cancer screenings for individuals taking this type of medicine.


Q: Does Hizaar have any effect on cholesterol levels?

A: Official documents state that the Hydrochlorothiazide component may affect certain metabolic measurements. Specifically, this ingredient has been associated with raising the serum levels of cholesterol and triglycerides. These potential effects may be monitored by your healthcare provider as part of your overall care.


Q: Is it necessary to have blood tests done regularly while on Hizaar?

A: Yes, regulatory constraints require that blood and urine tests may be needed regularly during treatment. These tests help monitor for changes in key body measurements, including renal (kidney) function and electrolyte levels, such as potassium, to manage potential adverse effects.


Q: Can Hizaar cause coughing like some other blood pressure medicines?

A: Cough is listed as a potential adverse reaction in clinical trial data for Hizaar. However, the incidence of cough associated with the Losartan component is reported to be similar to that of an inactive substance (placebo). This is lower than the incidence typically seen with medicines known as ACE inhibitors.


Q: How does Hizaar affect exercise and heat tolerance?

A: Official warnings state that taking this medicine may cause individuals to become overheated or dehydrated more easily during exercise or hot weather. Dehydration, which is a loss of too much water, can lead to very low blood pressure and serious electrolyte imbalance.


Q: Can Hizaar cause muscle cramps or spasms?

A: Official reports indicate that both muscle cramps and muscle spasm have been reported as adverse reactions. Severe muscle pain or weakness, in particular, may be a sign of changes in the body's potassium levels, which requires monitoring.


Q: How long does the body take to clear Hizaar after stopping treatment?

A: Pharmacokinetic studies describe how the body processes the medicine’s components. Losartan and its active form have elimination half-lives of approximately 2 hours and 6 to 9 hours, respectively. The Hydrochlorothiazide component has an elimination half-life that ranges between 5.6 and 14.8 hours.


Q: Is Hizaar known to interact with herbal supplements like St. John's Wort?

A: The regulatory label generally notes that other substances, including various herbal products, may affect the action of this medicine. For appropriate monitoring, it is important that a healthcare provider is aware of all herbal products and supplements being used.

How should Hizaar be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal instructions for Hizaar (losartan/hydrochlorothiazide) are set by regulatory agencies to maintain the quality and prevent environmental contamination.

Storage Requirement Official Condition
Temperature Store at controlled room temperature, 25 C (77 F).
Protection Keep container tightly closed and protect from light.
Child Safety Keep the medicine out of the reach of children.

The official labeling mandates that storage must not exceed 30 C (86 F) to maintain stability. For disposal of unused or expired tablets, regulatory guidance advises against flushing Hizaar down the toilet or pouring it down a drain. Patients should follow local guidelines by using drug take-back programs or by discarding the product safely with household trash according to documented instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hizaar found in:

A-Z Index: